In a significant development for emergency medicine and military-grade trauma response, the Canadian medical technology firm Flosonics Medical has been awarded a federal contract worth up to $70 million by the U.S. Department of Health and Human Services’ (HHS) Biomedical Advanced Research and Development Authority (BARDA). This strategic partnership aims to leverage Flosonics’ proprietary "FloPatch" wearable technology to develop "FloPredict," an advanced artificial intelligence (AI) algorithm capable of detecting internal hemorrhaging in the critical, often chaotic, minutes following a traumatic injury.
The contract, awarded under BARDA’s Burn and Blast Medical Countermeasures program, represents a pivotal shift in how clinicians might manage mass casualty events. By automating the interpretation of complex hemodynamic signals, the collaboration seeks to provide a lifeline for providers operating in environments where rapid, objective clinical data is traditionally scarce.
The Core Innovation: From ICU Monitoring to Field Trauma
Flosonics Medical has long been recognized for its FDA-cleared FloPatch, a wireless, wearable ultrasound sensor that has transformed how ICU clinicians monitor patient blood flow. Originally designed to guide intravenous (IV) fluid management—specifically to prevent the complications associated with fluid overload in sepsis patients—the device provides real-time, non-invasive hemodynamic assessments.
The new initiative, FloPredict, represents a sophisticated evolution of this technology. By applying machine learning and AI-driven hemodynamic analytics to the Doppler signals collected by the FloPatch, the system is being engineered to recognize the subtle physiological "signatures" that precede clinical deterioration due to internal bleeding.
"The goal," explained Dr. Jon-Emile Kenny, Chief Medical Officer at Flosonics, "is to create software that recognizes hemodynamic patterns preceding deterioration from hemorrhage and surfaces them early enough to act on."
Chronology of Development and Federal Engagement
The journey toward this partnership reflects a broader trend of public-private synergy in the medical technology sector.
- 2020: Flosonics receives FDA clearance for the original FloPatch, establishing its footprint in the intensive care unit (ICU) market.
- Early 2024: Flosonics engages with federal health security agencies to explore the application of wearable ultrasound in austere and battlefield environments.
- September 1, 2025: The U.S. government officially announces the contract award, marking the formal initiation of the FloPredict development program.
- Future Milestones: The initial $15 million in funding is earmarked for the initial development phase. Should the project meet specific technical and clinical milestones, the contract allows for additional options that could see total investment climb to $70 million.
The announcement was timed to coincide with broader news from the MedTech Innovator (MTI) ecosystem, which was selected as a key hub for the BARDA Accelerator Network (BAN). This timing underscores the federal government’s commitment to building a robust pipeline for next-generation medical devices designed to address public health security threats.
Supporting Data and the Clinical Necessity
In the context of trauma and mass casualty events—such as those resulting from natural disasters, industrial accidents, or combat—the primary cause of preventable death is often unrecognized or delayed treatment of internal hemorrhage.
Standard triage in these environments relies heavily on physical examination and intermittent vital sign monitoring, both of which can be delayed or obscured by external factors. Hemodynamic collapse can occur suddenly, and by the time traditional blood pressure cuffs or heart rate monitors signal a crisis, the patient may already be in irreversible shock.
FloPredict addresses this by:
- Continuous Surveillance: Unlike manual checks, the FloPatch provides a constant stream of data, allowing for the detection of trends over time.
- AI Pattern Recognition: By analyzing the Doppler signals, the algorithm can identify a drop in cardiac output or changes in vascular resistance that are imperceptible to the human eye but predictive of impending hemorrhagic shock.
- Resource Optimization: In a mass casualty setting, providers are forced to triage limited resources. By identifying which patients are deteriorating internally before they show overt symptoms, medical teams can prioritize care for those who need it most, effectively "stretching" the available medical staff.
Official Responses: A Milestone for Medical Technology
The announcement has been met with enthusiasm from both the private sector and federal officials, who see this as a template for future collaborations.
Joe Eibl, CEO and co-founder of Flosonics Medical, framed the partnership as a transformative moment for the company. "Partnering with the US government on a capability of this importance is a milestone for Flosonics," Eibl stated. "There is a real gap in how clinicians detect internal bleeding in the critical minutes after injury, and this award lets us build toward closing it. It also reflects the broader potential of FloPatch: the same real-time assessment clinicians rely on in critical care today can be extended to the settings where fast answers matter most."
The selection of Flosonics for this contract also aligns with the objectives of the MedTech Innovator (MTI) Vantage program, which serves as one of five strategic hubs for the BARDA Accelerator Network. As a key player in this network, MTI is tasked with accelerating the development of technologies that enhance national health security, ensuring that promising innovations like FloPredict do not languish in the "valley of death" between research and commercial deployment.
Implications: The Future of Battlefield and Emergency Medicine
The implications of the FloPredict algorithm extend far beyond the operating room. If the technology proves successful in clinical trials and field simulations, it could fundamentally alter the protocols for pre-hospital and combat casualty care.
Enhancing Military Readiness
The U.S. military has expressed a long-term interest in "prolonged field care"—the ability to keep injured soldiers alive for extended periods before they can be evacuated to a higher echelon of medical care. A wearable device that can alert a medic to early-stage internal bleeding would provide a critical window for intervention, such as the early administration of blood products or specialized fluids.
Reshaping Mass Casualty Triage
In civilian mass casualty events, such as school shootings or large-scale transit disasters, local EMS providers are often overwhelmed. The deployment of "smart" wearables that can wirelessly report patient status to a centralized command or a lead physician could allow for a tiered response, ensuring that the most critical patients are identified and stabilized rapidly.
A New Standard for Diagnostics
By integrating AI into the wearable ultrasound segment, Flosonics is effectively democratizing access to high-level diagnostics. Traditionally, hemodynamic monitoring required bulky equipment and highly trained specialists. If the FloPatch can interpret these signals autonomously, it could potentially allow less-specialized personnel—such as general duty nurses or combat medics—to perform functions previously reserved for critical care intensivists.
Challenges and the Path Forward
Despite the optimism surrounding the contract, the road to implementation involves significant hurdles. The primary challenge lies in the "signal-to-noise" ratio. Environments like a disaster scene or a battlefield are noisy, both acoustically and electronically. Ensuring that the FloPatch can maintain a clear signal on a patient in motion, in poor weather, or under extreme stress will be a primary focus of the development team.
Furthermore, the integration of the algorithm into existing medical workflows remains a key consideration. For FloPredict to be effective, the data it generates must be actionable and intuitive. The interface must be designed to minimize "alarm fatigue," a common issue in clinical settings where too many alerts can lead to provider desensitization.
As Flosonics begins the work of training the AI on robust datasets, the industry will be watching closely. The partnership with BARDA provides not just the necessary capital, but also access to the clinical and logistical expertise required to move a breakthrough technology from the lab to the field.
Conclusion
The $70 million investment in Flosonics is more than just a contract; it is a declaration that the future of trauma care lies at the intersection of portable ultrasound and artificial intelligence. By closing the gap in early hemorrhage detection, the FloPredict algorithm has the potential to save countless lives, offering a technological shield against the most dangerous of unseen injuries. As the project advances, it will serve as a bellwether for the efficacy of the BARDA Accelerator Network and the role of wearable AI in safeguarding global health security.
About the Author
